Laboratorios Farmaceuticos Rovi, S.A. Share Price

Equities

ROVI

ES0157261019

Pharmaceuticals

Market Closed - BME 09:05:18 31/05/2024 pm IST 5-day change 1st Jan Change
87.75 EUR -0.28% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. -4.10% +45.76%

Financials

Sales 2024 * 82Cr 89Cr 7.39TCr Sales 2025 * 91Cr 98Cr 8.19TCr Capitalization 454.72Cr 493.46Cr 41TCr
Net income 2024 * 18Cr 19Cr 1.59TCr Net income 2025 * 21Cr 23Cr 1.91TCr EV / Sales 2024 * 5.5 x
Net cash position 2024 * 3.82Cr 4.15Cr 344.8Cr Net cash position 2025 * 15Cr 16Cr 1.33TCr EV / Sales 2025 * 4.85 x
P/E ratio 2024 *
26.5 x
P/E ratio 2025 *
22 x
Employees 1,925
Yield 2024 *
1.28%
Yield 2025 *
1.52%
Free-Float 35.68%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Laboratorios Farmaceuticos Rovi, S.A.

1 day-0.28%
1 week-4.10%
1 month+6.75%
3 months+16.46%
6 months+54.76%
Current year+45.76%
More quotes
1 week
87.25
Extreme 87.25
90.95
1 month
79.10
Extreme 79.1
94.80
Current year
60.35
Extreme 60.35
94.80
1 year
37.96
Extreme 37.96
94.80
3 years
35.20
Extreme 35.2
94.80
5 years
19.10
Extreme 19.1
94.80
10 years
7.90
Extreme 7.9
94.80
More quotes
Managers TitleAgeSince
Chief Executive Officer - 01/94/01
Director of Finance/CFO - 01/00/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - 01/95/01
Director of Finance/CFO - 01/00/01
Chief Executive Officer - 01/94/01
More insiders
Date Price Change Volume
31/24/31 87.75 -0.28% 120,959
30/24/30 88 -0.11% 39,694
29/24/29 88.1 -0.45% 30,823
28/24/28 88.5 -1.01% 64,767
27/24/27 89.4 -2.30% 79,410

Delayed Quote BME, May 31, 2024 at 09:05 pm IST

More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
87.75 EUR
Average target price
89.44 EUR
Spread / Average Target
+1.92%
Consensus

Quarterly revenue - Rate of surprise